Q-omics provides the consensus-scored GDE1 profile across patient tissues and cancer cell-line models. GDE1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GDE1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, GDE1 RNA expression shows 18,967 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, KIRP, and ACC as cancer lineages where GDE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GDE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GDE1 survival associations across molecular data types. GDE1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GDE1 RNA expression–survival associations across cancer types. High GDE1 expression shows unfavorable associations in LIHC, LGG and ACC, but favorable associations in COAD, LUAD and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for GDE1 RNA expression.
This table summarizes GDE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GDE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GDE1 shows lower tumor expression in COAD and KIRC and higher tumor expression in KIRP, LIHC, BRCA and CHOL. The KIRP box plot shows higher GDE1 RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with GDE1 in patient tissues and cancer cell lines. In patient samples, GDE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GDE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
